New Leader Takes Charge at FDA's Drug Division

The FDA has selected Dr. Richard Pazdur to helm its drug division, bringing 26 years of experience to the role. This appointment follows a challenging period for the agency, marked by high staff turnover and declining morale.

A Leader in Cancer Drug Approvals

Dr. Pazdur is renowned for his work in approving numerous cancer drugs, which have saved lives and generated significant revenue for pharmaceutical companies. Now, he takes the reins of the Center for Drug Evaluation and Research (CDER), the FDA division responsible for most prescription and over-the-counter medicines.

CDER Faces Staffing and Regulatory Challenges

The CDER has endured substantial losses, with 1,000 employees departing this year due to layoffs, buyouts, and better opportunities in the pharmaceutical sector. Another FDA division, overseeing vaccines and gene therapies, has also faced significant struggles.

A Vision for the Future

Dr. Pazdur expressed honor in leading CDER during this transformative period in drug regulation. He aims to maximize the nation's potential in drug development. His predecessor, Dr. George Tidmarsh, recently stepped down, having criticized a new fast-track approval program for potential political interference.